Loading the security overview…
Where the tokens are
Standardised from the company’s filings, newest period first, labelled with the company’s own fiscal calendar. A line the company does not report is left off rather than shown as zero; margins and free cash flow are worked out here, and only where every input is present.
| Line item | Q2 FY262026-06-30 | Q1 FY262026-03-31 | Q4 FY252025-12-31 | Q3 FY252025-09-30 | Q2 FY252025-06-30 | Q1 FY252025-03-31 | Q4 FY242024-12-31 | Q3 FY242024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $7.80B | $6.96B | $7.93B | $7.77B | $7.08B | $6.67B | $7.57B | $7.55B |
| Cost of revenue | $1.58B | $1.45B | $1.62B | $1.57B | $1.50B | $1.54B | $1.58B | $1.57B |
| Gross profit | $6.22B | $5.52B | $6.30B | $6.20B | $5.58B | $5.13B | $5.99B | $5.97B |
| Gross margin | 79.8% | 79.2% | 79.5% | 79.8% | 78.8% | 76.9% | 79.1% | 79.1% |
| Research and development | $12.95B | $1.37B | $1.58B | $1.35B | $1.55B | $1.38B | $1.64B | $1.40B |
| Selling, general and administrative | $1.92B | $1.45B | $1.79B | $1.36B | $1.37B | $1.26B | $1.91B | $1.43B |
| Operating expenses | $16.62B | $2.93B | $4.32B | $2.87B | $3.11B | $2.89B | $3.54B | $5.08B |
| Operating income | −$10.39B | $2.59B | $1.98B | $3.33B | $2.47B | $2.24B | $2.45B | $888.00M |
| Operating margin | -133.2% | 37.1% | 25.0% | 42.8% | 34.9% | 33.6% | 32.4% | 11.8% |
| EBITDA | −$7.95B | $3.38B | $3.61B | $4.18B | $3.36B | $3.19B | $3.13B | $3.83B |
| Interest expense | −$247.00M | −$240.00M | −$255.00M | −$256.00M | −$254.00M | −$260.00M | −$249.00M | −$238.00M |
| Income before taxes | −$10.25B | $2.58B | $2.08B | $3.64B | $2.43B | $1.65B | $2.17B | $956.00M |
| Income taxes | $242.00M | $559.00M | −$105.00M | $589.00M | $468.00M | $334.00M | $385.00M | −$297.00M |
| Net income | −$10.50B | $2.02B | $2.18B | $3.05B | $1.96B | $1.32B | $1.78B | $1.25B |
| Net margin | -134.5% | 29.0% | 27.5% | 39.3% | 27.7% | 19.7% | 23.5% | 16.6% |
| EPS, basic | −$8.45 | $1.63 | $1.76 | $2.46 | $1.57 | $1.06 | $1.43 | $1.00 |
| EPS, diluted | −$8.45 | $1.61 | $1.74 | $2.43 | $1.56 | $1.04 | $1.41 | $1.00 |
| Diluted shares | 1.24B | 1.25B | 1.25B | 1.25B | 1.26B | 1.26B | 1.27B | 1.25B |
Figures describe Gilead Sciences shares, not any token. As of Aug 6, 2026, from Massive's standardised financials. The company reports these figures; a token's issuer holds the shares and reports nothing of its own here.